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MiceAbstract Valproic acid (VPA) is a widely used antiepileptic medication and has teratogenic effects
in both animals and humans. The objective of the current study was to investigate the effects of vita-
min E (Vit-E) on VPA induced cytogenotoxicity and hepatotoxicity in male albino mice (Mus mus-
culus). Genotoxicity and cytotoxicity were evaluated by bone marrow chromosomal aberration
assay and mitotic index respectively, while hepatic dysfunctions were evaluated by light and electron
microscopy.
80 mice were used, they were divided into eight groups, group one (G1) served as negative control
group and the other seven groups were administered VPA and Vit-E as follows: G2 received VPA
(100 mg/kg) and G3–G5 received Vit-E at doses 50, 100 and 200 mg/kg respectively for 21 days.
While the treated groups (G6–G8) were administrated with Vit-E in concomitant with VPA for
21 days. The positive control animals administered VPA alone showed toxic histological and genet-
ical manifestations (at P < 0.05). All the histological alterations in liver were greatly abated using
Vit-E with signiﬁcant reduction in chromosomal aberrations and elevation in mitotic index
(P< 0.05). On the basis of the present results, Vit-E at dose 100 mg/kg appeared more potent in
exerting the ameliorative effect.
ª 2014 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. All rights
reserved.Introduction
Epilepsy is a relatively common neurological condition caused
by an imbalance of normal excitatory and inhibitory forces inthe brain (Holmes and Zhao, 2008). Conventional treatment of
epilepsy consists of antiepileptic drugs and surgical interven-
tion. As many patients with epilepsy are not surgical candi-
dates, medical therapy is presently the most common form
of epilepsy treatment. There are currently more than 20
antiepileptic drugs approved by the U.S. Food and Drug
Administration for the treatment of epilepsy (Lee and
Chung, 2010). The concern that epilepsy or its treatment
may be causally implicated in the development and subsequent
course of several health conditions is an area of ongoing inter-
est. The spectrum of comorbidity encompasses not only neuro-
128 E.M. Abdella et al.psychiatric disorders such as dementia, learning disabilities
and depression, but also non-neurological conditions such as
cancer (Singh et al., 2005).
Valproic acid (VPA) is a commonly prescribed antiepileptic
drug used to treat a wide variety of seizure disorders
(Chapman et al., 1982). Furthermore, VPA has also proven
to be effective in the treatment of bipolar disorder (Bowden,
2003), migraine prophylaxis (Freitag, 2003), and neuropathic
pain (Covington, 1998). Despite its effectiveness and wide-
spread use, valproic acid is teratogenic in both animals and
humans (Defoort et al., 2006).
Severe side effects are associated with VPA treatment such
as hepatotoxicity, thrombocytopenia, platelet aggregation and
pancreatitis (Kis et al., 1999; Ibrahim, 2012). Although the
mechanism of liver toxicity remains elusive, oxidative stress,
as a result of overproduction of reactive oxygen species
(ROS) and compromised antioxidant capacity, has been
hypothesized to play a role in the etiology of toxicity
(Pippenger et al., 1991). In particular ROS and free radicals
show genotoxic activity (Pippenger, 2003) and number of stud-
ies have investigated the possibility that VPA treatment is
associated with oxidative stress in patients (Cengiz et al.,
2000) and in animal models (Tong et al., 2005).
In order to overcome the potential harmful effect of free
radicals and to reduce the damage by oxidants, many natural
substances have been tried as antioxidants. Vitamin E emerged
as an essential, fat soluble nutrient that functions as an antiox-
idant in the human body. It is essential, because the body can-
not manufacture its own vitamin E so foods and supplements
must provide it. Vitamin E term includes eight naturally occur-
ring components including the respective a, b, c, and d deriv-
atives of tocopherol and tocotrienol. Among them, RRR-a-
tocopherol is by far the most abundant lipid-soluble antioxi-
dant in humans and it is present in cellular and sub-cellular
membranes (Cordero et al., 2010). Vit-E represents one of
the most fascinating natural resources that have the potential
to inﬂuence a broad range of mechanisms underlying human
health and disease (Catalgol and Ozer, 2012). Vitamin E may
effectively minimize oxidative stress, lipid peroxidation and
toxic effects of reactive oxygen species in biological systems
(Claycombe and Meydani, 2001).
Therefore, the present study was undertaken to evaluate the
possible protective effect of vitamin E against valproic acid-
induced chromosomal abnormalities in bone marrow cells
and histological alterations in liver tissue of male albino mice
(Mus musculus).
Materials and methods
Chemicals
Sodium valproate (salt of valproic acid) was purchased from
pharmacy in the form of tablets with trade name Depakine
(Sanoﬁ Synthelabo, France), each containing 200 mg of
sodium valproate. Vitamin E was purchased from pharmacy
in the form of capsules, each containing 100 mg of vitamin E
(Cairo Pharm. & Chem. Ind. Co., Cairo, Egypt). All other
chemicals were obtained from Sigma (St. Louis, MO, USA).Experimental animals
The experimental animals used in this work were 80 ran-
domly bred adult males of laboratory mice M. musculus
(20–30 g in weight). Animals were obtained from Ophthal-
mology research institute, Giza, Egypt. Experiments were
performed as per internationally followed ethical standards
and according to the Guide for the Care and Use of Labora-
tory Animals of the National Institutes of Health (Institute of
Laboratory Animal Resources, 1996). All animals were
housed in plastic cages with wired covers and kept under nor-
mal laboratory conditions. They were fed a standard com-
mercial diet (ATMID Company, Egypt) and tap water
ad libitum.
Experimental design
A single dose (100 mg/kg dissolved in distilled water) of VPA
was selected with reference to the dose range of the cytotoxic-
ity and genotoxicity of VPA (Lee et al., 2007). However, Vit-E
concentrations were 50, 100 and 200 mg/kg (These concentra-
tions prepared using corn oil). These concentrations were
selected according to (Aktas et al., 2010; Catalgol and Ozer,
2012).
Experimental groups were organized as eight groups
including 10 animals/each. In each group ﬁve mice were used
for cytogenetic analysis while the others were used for histopa-
thological studies. The animals of group one (G1) served as
negative control receiving corn oil (10 ml/kg) through oral
intubation daily for three weeks. The animals of G2 received
intraperitoneal (i.p.) injection of VPA (100 mg/kg) daily for
three weeks. In G3, G4 and G5, Vit-E at doses 50,100 and
200 mg/kg respectively were given to the animals through oral
intubation once/day for 21 days. The animals of G6, G7 and
G8 received oral administration of Vit-E (50,100 and
200 mg/kg respectively) once/day for 21 days simultaneously
with i.p. injection of VPA.
Cytogenetic assay
Bone marrow cell preparations for the analysis of chromo-
somal aberrations and mitotic indices were conducted by
the colchicine-hypotonic technique. 24 h after completion of
the treatment period, ﬁve animals from each group were sac-
riﬁced by cervical dislocation. Colchicine was given at the
dose of 4 mg/kg intraperitoneally 2 h prior to sacriﬁcing the
animals. The bone marrow smears of animals in each group
were prepared according to Preston et al. (1987). For each
group, slides were stained with Giemsa staining method and
50 well spread metaphase plates/animal were analyzed for
chromosomal aberrations and the number of mitotic cells in
1000 cells/animal. The percentage of suppressed aberrant cells
was calculated according to Shukla and Taneja (2002) as
follows:
100 of aberrant cells in G6 or G7 or G8
% of aberrant cells in G2
 
 100
Table 1 Chromosomal aberrations induced in bone marrow cells of mice after treatment with VPA and 3 different doses of Vitamin E (Vit-E).
Groups Number
of metaphase
Structural Chromosomal Aberrations Numerical Chromosomal Aberrations
Chromatid
Break
Chromatid
Deletion
Chromatid
Gap
Ring
Chromo.
Fragment End to
End Assoc.
Centric
Fusion
Centromeric
Attenuation
TSAa Polyploidy Endomitosis TNAa
G1
(Corn oil)
250 3
(1.20)
2
(0.80)
1
(0.40)
1
(0.40)
1
(0.40)
0 0 0 8
2.20 ± 0.860
1
(0.40)
3
(1.20)
4
0.80 ± 0.200
G2
(VPA)
250 18
(7.20)
23
(9.20)
0 1
(0.40)
6
(2.40)
5
(2.00)
4
(1.60)
14
(5.60)
71b
14.20 ± 1.529
3
(1.20)
12
(4.80)
15b
3.00 ± 0.710
G3
(Vit50)
250 4
(1.60)
7
(2.80)
2
(0.80)
0 0 0 0 2
(0.80)
15c
3.00 ± 0.710
3
(1.20)
1
(0.40)
4c
0.80 ± 0.490
G4
(Vit100)
250 3
(1.20)
7
(2.80)
1
(0.40)
0 3
(1.20)
1
(0.40)
0 0 15c
3.00 ± 0.710
1
(0.40)
2
(0.80)
3c
0.60 ± 0.400
G5
(Vit200)
250 4
(1.60)
9
(3.60)
0 0 1
(0.40)
0 0 10
(4.00)
24b
4.80 ± 0.800
7
(2.80)
8
(3.20)
15b
3.00 ± 1.000
G6
(Vit50 ± VPA)
250 13
(5.20)
18
(7.20)
0 0 1
(0.40)
2
(0.80)
1
(0.40)
9
(3.60)
44d
8.80 ± 0.200
4
(1.60)
13
(5.20)
17e
3.40 ± 0.510
G7
(Vit100 ± VPA)
250 14
(5.60)
15
(6.00)
0 1
(0.40)
5
(2.00)
4
(1.60)
0 7
(2.80)
46d
9.20 ± 1.068
3
(1.20)
5
(2.00)
8e
1.80 ± 0.680
G8
(Vit200 ± VPA)
250 19
(7.60)
11
(4.40)
1
(0.40)
0 5
(2.00)
1
(0.40)
5
(2.00)
9
(3.60)
51d
10.20 ± 0.374
3
(1.20)
8
(3.20)
11e
2.20 ± 0.860
TSA: total structural aberrations; TNA: total numerical aberrations.
a Mean ± SE data in brackets% P < 0.05 signiﬁcant.
b Signiﬁcantly increased with –ve control.
c Not signiﬁcant with ve control.
d Signiﬁcantly decreased with +ve control.
e Not signiﬁcant with +ve control.
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Table 2 Clastogenetic changes induced in bone marrow cells of mice in all experimental groups.
Groups Number ofa Cells
with one aberration
Number of Cellsa
with more than
one aberration
Incidence ofa
aberrant cells %
Number ofa
aberration/cell
Suppressive
eﬀect %
Mitotic indexa
Corn-oil 2.40 ± 0.600 0 4.80 ± 0.600 0.032 ± 0.020 74.04 ± 1.319
VPA. 13.20 ± 1.241 2.00 ± 0.316 30.40 ± 1.460 0.344 ± 0.034 59.76 ± 3.771
Vit 50 3.80 ± 0.581 0 7.60 ± 0.580 0.076 ± 0.011 72.04 ± 0.866
Vit 100 3.60 ± 0.678 0 7.20 ± 0.680 0.072 ± 0.013 71.21 ± 1.430
Vit 200 6.60 ± 1.166 0.60 ± 0.245 13.20 ± 1.280 0.156 ± 0.028 69.69 ± 2.825
Vit 50 + VPA. 8.60 ± 0.678 1.80 ± 0.374 20.80 ± 0.400 0.244 ± 0.007 31.578 64.92 ± 0.710
Vit 100 + VPA. 8.80 ± 0.916 1.00 ± 0.447 19.60 ± 0.730 0.216 ± 0.016 35.526 65.43 ± 1.556
Vit 200 + VPA. 10.00 ± 1.049 1.20 ± 0.374 22.20 ± 0.800 0.248 ± 0.013 26.973 62.25 ± 0.979
a Mean ± SE data.
Table 3 Statistical comparison between the groups according to Incidence of aberrant cells %, number of aberration/cell and mitotic
index.
Group -Ve Control G2 G3 G4 G5 G6 G7
A B C A B C A B C A B C A B C A B C A B C
G2 s s s
G3 ns ns ns s s s
G4 ns ns ns s s s ns ns ns
G5 s s ns s s s s s ns s s ns
G6 s s s s s s s s s s s s s s ns
G7 s s s s s s s s s s s s s s ns ns ns ns
G8 s s s s s ns s s s s s s s s s ns ns ns ns ns ns
A = incidence of aberrant cells %.
B = number of aberration/Cell.
C = mitotic index.
s = signiﬁcant at P< 0.05.
ns = not signiﬁcant at P< 0.05.
130 E.M. Abdella et al.Histopathological assay
Preparation of parafﬁn section
24 h after completion of the treatment period, mice in each
group were sacriﬁced under mild anesthesia by diethyl ether
and dissected quickly to remove the liver. Liver tissues were
ﬁxed in 10% buffered formalin and processed for prepara-
tion of 5 lm thick sections and were stained with Haema-
toxylin and Eosin (H&E) according to Bancroft et al.
(1996).
Ultrastructure preparations
Specimens from liver were cut into small pieces measuring
about 1mm3 and ﬁxed in 2.5% phosphate buffered glutaralde-
hyde. After postiﬁcation with 1% osmic acid, they were dehy-
drated with acetone and semi-thin sections of tissue samples
embedded in araldite were stained with toluidin blue
(Bozzola and Russell, 1999). Then, the thin sections were
stained with uranyl nitrate-lead and evaluated under a Joel
CX100 transmission electron microscope and microphoto-
graphs were taken.
Statistical analysis
Statistical analysis for the difference in the mean number of
chromosomal aberrations and mitotic index between groupswas carried out using the student’s t-test (P< 0.05 was consid-
ered signiﬁcant).Results
Cytogenetic assay
According to the cytogenetic results illustrated in Table 1, 10
structural and numerical chromosomal aberrations were deter-
mined in the control and the experimental groups. The results
revealed that when 100 mg/kg of VPA was given to mice daily
for three weeks, it induced a high frequency of chromosomal
aberrations. The chromatid breaks and deletions were the most
frequent structural chromosomal aberrations while endomito-
sis was the most frequent numerical chromosomal aberration.
Other structural and numerical aberrations increased signiﬁ-
cantly at (P< 0.05) over the control group. While the mitotic
index was signiﬁcantly decreased to 59.76 ± 3.771 compared
to control value of 74.04 ± 1.319 (P< 0.05), indicating bone
marrow cytotoxicity (Table 2). Also, the data illustrated in
Table 1 exposed that, when Vit-E was given alone at doses
50, 100 and 200 mg/kg once daily for three weeks, it failed to
induce or increase the number of some chromosomal aberra-
tions over the control group (G1) except G5 increased signiﬁ-
cantly (at P < 0.05) in chromatid deletions, centromeric
Protective role of vitamin E against valproic acid 131attenuation, polyploidy, endomitosis and value of total numer-
ical aberrations. Vit-E was also found to be not cytotoxic at
the given doses (50, 100 and 200 mg/kg), as there were no sig-
niﬁcant changes (at P < 0.05) in mitotic index over G1 (Tables
2 and 3).
On the other hand, administration of Vit-E in concomitant
with VPA caused a signiﬁcant decrease in rates of clastogenetic
changes compared with the VPA treated group (Tables 1 and
2). All types of chromosomal aberrations induced by VPA
including breaks, deletions, fragments, ring chromosomes,
end to end association, centric fusion, centromeric attenuation,
and other multiple damages were found to be reduced by Vit-E
but still signiﬁcantly higher than the negative control group
(G1) (Table 1) and (Fig. 1).
The mitotic index in the groups treated with Vit-E simulta-
neously with VPA was found to be increased signiﬁcantly
(P< 0.05) over G2 for the doses of 50 and 100 mg/kg, indicat-
ing anti-cytotoxicity toward VPA but the mitotic index was
found to be increased not signiﬁcantly (P< 0.05) over G2
for the dose of 200 mg/kg of Vit-E (Tables 2 and 3). The per-
centage of aberrant cells which was found to be 30.40 ± 1.460
in VPA treated animals, was signiﬁcantly decreased to
20.80 ± 0.400, 19.60 ± 0.730 and 22.20 ± 0.800 (P< 0.05)
by Vit-E at doses 50, 100 and 200 mg/kg respectively (Tables
2 and 3). Also, a signiﬁcant decrease in the number of aberra-
tions per cell was observed in G6, G7 and G8 over the VPA
treated group (G2) (Tables 2 and 3). The calculated suppres-
sive effects of Vit-E at doses 50, 100 and 200 mg/kg were
31.578%, 35.526% and 26.973%, respectively (Table 2)
(Fig. 2).
Histopathological assay
Light microscope observation
The histological examination of the liver sections of control
animals (G1) showed its normal architecture (Fig. 3a). Thecc
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Figure 1 Shows the number of total structural and total numerical
concomitant with VPA).normal liver consists of a number of hepatic lobules. Each lob-
ule is formed of cords of hepatocytes radiating from the central
vein. The cell cords are separated by narrow blood sinusoids
lined by Kupffer cells and endothelial cells. The hepatocytes
are large polyhedral with acidophilic cytoplasm and darkly
stained nuclei. Few of these cells are bi-nucleated (Fig. 3a).
However, mice given vitamin E had nearly normal liver archi-
tecture and organization, except for inﬂammatory cell inﬁltra-
tion noticed in the portal area of liver sections of animals
treated with vitamin E at dose 200 mg/kg (Fig. 3b).
Histological assessment of the liver three weeks after
administration of valproic acid showed inﬂammatory cell inﬁl-
tration, hydropic degenerated hepatocytes (Fig. 3c–e and h)
and highly dilated hyperemic central and portal veins
(Fig. 3c–e). Hemorrhage in hepatic parenchyma was observed
and kupffer cells were actively proliferating, markedly
increased in size and number and some of them were pushed
into the lumina of sinusoids (Fig. 3f). In addition, fatty
changes and newly formed bile ductules were observed in the
hepatocytes (Fig. 3g).
Treatment with 50 and 100 mg/kg of vitamin E in concom-
itant with VPA greatly ameliorated the hepatic histopatholo-
gical lesions and the hepatic parenchyma attained nearly
normal structure and organization (Fig. 4c and d respectively).
Rarely, liver tissues of mice treated with 200 mg/kg of vitamin
E in concomitant with VPA showed markedly dilated portal
vein, inﬂammatory cells inﬁltration (Fig. 4a) and mild hydro-
pic degeneration in hepatic cells (Fig. 4b).
Ultrastructure results
No pathological changes were observed in the ultrastructure of
mice’s liver cells in the control group (G1) (Fig. 5a and b). The
cytoplasmic organelles as well as the nuclei of the hepatocytes
exhibited normal appearance. The cytoplasm contained
numerous mitochondria dispersed all over the cytoplasm.d
d
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chromosomal abberations in Vit-E treated groups (alone and in
Figure 2 (a) Metaphase spread from mouse bone marrow cells showing normal chromosome spread. (b) Metaphase spread from mouse
bone marrow cells showing ring chromosome (›). (c) Metaphase spread from mouse bone marrow cells showing a cell with more than one
aberration [chromatid break (thin arrow) and chromatid gap (bold arrow)]. (d) Metaphase spread from mouse bone marrow cells showing
a cell with more than one aberration [deletion (white arrow), fragment (bold black arrow) and end to end association (thin black arrow)].
(e) Metaphase spread from mouse bone marrow cells showing centric fusion aberration (›). (f) Metaphase spread from mouse bone
marrow cells showing centric attenuation aberration. (g) Metaphase spread from mouse bone marrow cells showing endomitosis. (h)
Metaphase spread from mouse bone marrow cells showing polyploidy.
132 E.M. Abdella et al.The mitochondria were spherical in shape with well-developed
cristae, while the rough endoplasmic reticulum was closely
packed parallel with ﬂattened cisternae studded with ribo-
somes. Also, considerable electron-dense glycogen rosettes orgranules were clearly detected. The nucleus was rounded with
a distinct nuclear envelop and the nucleoplasm showed
aggregations of euchromatin and heterochromatin (Fig. 5a).
In addition, the hepatic sinusoid, localized between the
Figure 3 (a) A photomicrograph of liver section of control mice administered corn oil showing the characteristic histological structures;
central vein (CV), hepatocytes (HC), sinusoids (S) and kupffer cells (ﬂ). (H&E X 400). (b) A photomicrograph of liver section of control mice
administered200 mg/kgof vitaminE showing inﬂammatory cells inﬁltration (IF), normal hepatocytes (HC)and sinusoids (S) (H&E·400). (c)A
photomicrograph of liver section ofmice given valproic acid (100 mg/kg) for 3 weeks showing inﬂammatory cells inﬁltration (IF), highly dilated
hypermic central vein (CV) and hydropic-degenerated hepatocytes (HC). (H&E ·400). (d) A photomicrograph of liver section of mice given
valproic acid (100 mg/kg) for 3 weeks showing inﬂammatory cells inﬁltration (IF) in the portal area, hydropic-degenerated hepatocytes (HC)
and newly formed bile ductules (BD). (H&E ·400). (e) A photomicrograph of liver section of mice given valproic acid (100 mg/kg) for 3 weeks
showing hyperemic portal vein (PV), hydropic-degenerated hepatocytes (.); somebinucleated (BH) and others annucleated (AH). (H&E·400).
(f) A photomicrograph of liver section ofmice given valproic acid (100 mg/kg) for 3 weeks showing hemorrhage (H) in the hepatic parenchyma,
dilated sinusoids(S) and swelling inkupffer cells (K) (H&E·400). (g)Aphotomicrographof liver section ofmice given valproic acid (100 mg/kg)
for 3 weeks showing ﬁbrosis in the portal area (ﬂ), newly formedbile ductules (BD), hyperemic portal vein (PV) and large number of hepatocytes
undergo fatty change (F) (H&E ·400). (h) A photomicrograph of liver section of mice given valproic acid (100 mg/kg) for 3 weeks showing
inﬂammatory cells inﬁltration (IF), hydropic-degenerated hepatocytes (HC) and some cells lost their nuclei (AH). (H&E ·400).
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Figure 4 (a) A photomicrograph of liver section of mice treated with vitamin E (200 mg/kg) in concomitant with valproic acid for
3 weeks showing severe dilation of portal vein (PV), in addition to inﬂammatory cells inﬁltration (IF) in the portal area (H&E ·400). (b) A
photomicrograph of liver section of mice treated with vitamin E (200 mg/kg) in concomitant with valproic acid for 3 weeks showing mild
hydropic degeneration in hepatic cells (HC) (H&E ·100). (c) A photomicrograph of liver section of mice treated with vitamin E (50 mg/kg)
in concomitant with valproic acid for 3 weeks showing mild nearly normal structure of hepatic cells (›). (H&E ·100). (d) A
photomicrograph of liver section of mice treated with vitamin E (100 mg/kg) in concomitant with valproic acid for 3 weeks showing nearly
normal structure of hepatic cords, central vein (CV), hepatocytes (HC), sinusoids (S) and kupffer cells (ﬂ). (H&E X 100).
134 E.M. Abdella et al.hepatocytes and lined with a kupffer cell, was also shown in
(Fig. 5b). However, electron microscopic examinations of
hepatic cells at high dose of Vit-E (200 mg/kg) showed that
irregular nucleus, debris of mitochondria and few lysosomes
(Fig. 5c) of some cells.
In valproic acid treated mice (G2), nearly complete disinte-
gration of most cellular contents except few number of mito-
chondria, rough endoplasmic reticulum and few glycogen
was observed (Fig. 6a). While swelling in mitochondria and
fragmented rough endoplasmic reticulum was observed in
(Fig. 6b). Also the cytoplasm of these cells had a large number
of lipid droplets and irregular pyknotic nucleus (Fig. 6c). Some
of the cells presented variation in size and shape of mitochon-
dria and few lysosomes which were electron dense in appear-
ance (Fig. 6d). In addition, hepatic sinusoid, as displayed in
(Fig. 7a) was markedly dilated and ﬁlled with blood and
vacuoles.
Examination of liver from mice treated with valproic acid
and vitamin E (100 mg/kg) showed normal structure of mito-
chondria, nucleus and cell membrane (Fig. 7d) and normal gly-
cogen distribution in the cytoplasm but some mitochondria
showed loss of cristae and few cytoplasmic vacuoles were still
present (Fig. 7c). Also, the hepatic sinusoid contained little or
no cell debris (Fig. 7b).Discussion
The present investigation showed mice treated with valproic
acid (VPA) impaired several histopathological alterations in
liver tissues, increase in number of chromosomal abnormalities
and decrease in mitotic index of bone marrow cells. These ﬁnd-
ings were associated with increase in the formation of toxic
VPA metabolites (Baran et al., 2004) or altered antioxidant
enzyme activities (Graf et al., 1998).
The results of the present study suggested that valproic acid
is capable of being genotoxic and cytotoxic and these results
were in agreement with previous studies that examined the
genotoxicity of valproic acid by analyzing sister chromatid
exchanges in peripheral lymphocytes from patients treated
with it. Sister chromatid exchanges occur via the homologous
recombination (HR) repair pathway and are used as an indica-
tor of chromosomal instability after exposure to a potentially
mutagenic agent (Defoort et al., 2005). However, further evi-
dences indicated that valproic acid may contribute to genomic
instability because valproic acid alters chromatin structure
because it can function as a histone deacetylase inhibitor, lead-
ing to acetylation of histone tails (Marchion et al., 2005; Wu
et al., 2010). This change in the chromatin structure changes
the conformation of DNA, making it more susceptible to
Figure 5 (a) Electron micrograph of hepatocytes of control mice administered corn oil showing normal appearance of nucleus (N),
rough endoplasmic reticulum (RER), mitochondria (M) and glycogen rosettes (g). Scale bar 2 lm. (b) Electron micrograph from control
mice administered corn oil showing a hepatic sinusoid separated from the adjacent hepatocyte by the space of disse, kupffer cells (KC),
mitochondria (M) and red blood cells (RBCs). Scale bar 2 lm. (c) Electron micrograph of hepatocytes of Vit-E (200 mg/kg) administered
mice for three weeks showing irregular nucleous (N), depris mitochondria (M), lysosomes (LY) and rough endoplasmic reticulum (RER).
Scale bar2 lm.
Protective role of vitamin E against valproic acid 135DNA damage, including double-strand breaks (Coyle et al.,
2005).
In the present study, treatment of mice with valproic acid
resulted in obvious changes in the general architecture of the
liver which was in agreement with Baran et al. (2004), Khan
et al. (2005) and Tong et al. (2005).
The hydropic degeneration, observed in the present study
that is in agreement with the result of Raza et al. (2000) and
Ibrahim (2012), is probably due to anoxia which may lead to
the disturbance of the ionic milieu of the cell that entailsretention of water and sodium with concomitant loss of potas-
sium from the cells leading to cellular swelling (Boyd, 1970). In
addition, the observed vascular dilatation may represent an
adaptive process as an attempt to overcome this oxygen deﬁ-
ciency which, when prolonged, may be the cause of atrophic
cells’ formation. Atrophied liver cells probably later, result in
the presence of necrotic patches. Also, this dilatation may be
attributed to the hepatic congestion that results from direct
action of the treatment on the vessel wall or the back pressure
in the portal tract (Lindop and Dargie, 1992).
Figure 6 (a) Electron micrograph of hepatocytes of mice given valproic acid (100 mg/kg) for 3 weeks showing nearly complete
disintegration of most cellular contents (black arrow) except few number of mitochondria (M), nucleus (N), lipid droplets (L) and
abnormal cell membrane (white arrow). Note the break down of rough endoplasmic reticulum (RER) and high depletion in glycogen
content (g). Scale bar 2 lm. (b) Electron micrograph of hepatocytes of mice given valproic acid (100 mg/kg) for 3 weeks showing swollen
mitochondria (M), fragmented rough endoplasmic reticulum (RER) and vacuoles (V). Scale bar 500 nm. (c) Electron micrograph of
hepatocytes of mice given valproic acid (100 mg/kg) for 3 weeks showing large number of lipid droplets (L), irregular nucleus (N) and cell
membrane (›). Scale bar 2 lm. (d) Electron micrograph of hepatocytes of mice given valproic acid (100 mg/kg) for 3 weeks showing
mitochondria (M), rough endoplasmic reticulum (RER), nucleus (N), lysosomes (LY) and vacuoles (V). Scale bar 2 lm.
136 E.M. Abdella et al.On the other hand, newly formed bile ductules, seen in the
present investigation, may mirror a cholestasis process, which
represent the early changes following the biliary obstruction.
In this process, bile ﬁrst accumulates in hepatocytes, bile can-
aliculi and kupffer cells. Subsequently, the large bile ducts
become dilated and ﬁlled with bile. Extravasation of bile then
may be associated with infalmmatory reaction. This particu-
larly involves the portal tracts, which become oedematous
and inﬁltrated with different inﬂammatory cells around the
bile ducts-cholangitis (Annette-Mowat et al., 1992).
Microvesicular steatosis (which characterizes VPA-associ-
ated liver injury) possibly occurs via interference with theprocess of fatty acid i-oxidation (through reactive intermedi-
ates which inhibit key enzymes) (Baillie, 1992) or by the
possible idiosyncratic production of toxic VPA metabolites
(Stephens and Levy, 1992).
Concerning the cytotoxic effects on the ultrastructure of the
hepatocytes, valproic acid was shown to be a destructive com-
pound for most of the intracellular organelles (Sobaniec-
otowska, 1997; Neumana et al., 2001).
The present investigation showed that treating mice with
VPA impaired cytoplasmic vacuolization and mitochondrial
alterations that included swelling and abnormality of cristae.
These effects reﬂected most of their prominently response to
Figure 7 (a) Electron micrograph of a sinusoid of mice given valproic acid (100 mg/kg) for 3 weeks showing activated kupffer cells (KC)
and vacuoles (V). Scale bar 2 lm. (b) Electron micrograph of a sinusoid of mice given vitamin E (100 mg/kg) in concomitant with valproic
acid showing that the sinusoid contains little depris (›), normal kupffer cell (KC), mitochondria (M) and red blood cells (RBCs). Scale bar
2 lm. (c) Electron micrograph of hepatocytes of mice given vitamin E (100 mg/kg) in concomitant with valproic acid for 3 weeks showing
little depris mitochondria (M), vacuoles (V), normal glycogen rosettes (g) and regular nucleus (N). Scale bar 2 lm. (d) Electron
micrograph of hepatocytes of mice given vitamin E (100 mg/kg) in concomitant with valproic acid for 3 weeks showing normal cell
organelles; nucleus (N), mitochondria (M), rough endoplasmic reticulum (RER) and normal cell membrane (›). Scale bar 2 lm.
Protective role of vitamin E against valproic acid 137toxic insult and were in agreement with Tein et al. (1993) who
indicated that the ultrastructural changes observed were char-
acterized by myeloid bodies, lipid droplets, vacuoles and mito-
chondrial abnormalities.
The altered mitochondrial structure in VPA-treated cells
may have been the result of VPA inhibition of b–oxidation.
This mechanism may also explain the slight decrease in cell via-
bility observed when hepatocytes were treated with VPA
(Neumana et al., 2001). Different theories have been proposed
for the mechanism of valproate-induced hepatotoxicity. Val-
proate is a short-chain fatty acid that requires carnitine for oxi-
dation. One theory is that valproate combines with carnitine
within the mitochondria via carnitine-acyl transferases, result-
ing in valproyl carnitine ester, which is then transported out ofthe mitochondria and is eliminated in the urine, thus depleting
body carnitine stores so no adequate ratio of fatty acyl-CoA
compounds to free CoA inside the mitochondria; therefore, a
lack of carnitine results in the accumulation of acyl com-
pounds, which may be toxic to the mitochondria. Another
mechanism involves valproate’s inhibition of mitochondrial
oxidation of long-chain fatty acids by the formation of valp-
royl CoA, which sequesters unbound CoA and decreases its
availability (Romero-Falcon et al., 2003).
Vitamin E (Vit-E) is an essential element of human nutri-
tion. Many of its actions are related to its antioxidant proper-
ties (Louis, 1986). The antioxidant action of Vit-E is also
signiﬁcant to the genetic material stability because autoxida-
tion products of lipids and unsaturated fatty acids are highly
138 E.M. Abdella et al.toxic mutagenic substances (Vaca et al., 1988). Many in vitro
and in vivo studies have indicated a relationship between Vit-
E supplementation and reduced risk of cancer (Albanes
et al., 2000: Kune and Watson, 2006) and DNA damage
(Mozdarani and Salimi, 2006; Lorenzetti et al., 2007).
In the current study, administration of vitamin E abated the
chromosomal damages, cytotoxic effects and hepatopatholog-
ical lesions produced by valproic acid. These results were in
agreement with the ﬁndings of Yassa et al. (2011), who con-
cluded that vitamin E, as an antioxidant, has protective effect
against diazinon genotoxic effects by inactivating or scaveng-
ing free radicals generated following pesticides exposure. Fur-
thermore, Aly et al. (2009) indicated that vitamin E inhibited
the DNA damage induced by ﬂouroquinolones drug (cipro-
ﬂoxacin) in dose and time dependent manner.
Also, several studies suggested indirectly that the produc-
tion and the presence of toxic metabolites were only responsi-
ble for mutagenic effects and hepatic toxicity of VPA; this
toxicity could be expected to decrease or even disappear, due
to use of antioxidant agent like Vit-E (Na et al., 2003;
Spaniol et al., 2003; Aly et al., 2009).
Chronic treatment with VPA has been shown to decrease
the levels of antioxidants such as vitamin E and glutathione
peroxidase further suggesting the role of oxidative stress
(Baran et al., 2004). Moreover, many studies have shown pro-
tective effect of vitamin C and vitamin E against VPA induced
hepatotoxicity (Jurima-Romet et al., 1996).
These scavengers would be expected to reduce any free rad-
ical metabolites and thus prevent lipid peroxidation and toxic-
ity. The decrease in toxicity could simply be a consequence of
Vit-E stabilizing the hepatocyte membranes, allowing less lac-
tate dehydrogenase (LDH) to be released into the surrounding
media and thus decreasing the LDH index (Buchi et al., 1984).
The results indicated that Vit-E treated mice, the micro-
scopic examination of the liver section showed normal histo-
logical structure of hepatic cells at 50 and 100 mg/kg doses,
but high dose of Vit-E (200 mg/kg) showed inﬂammatory cell
inﬁltration. High dose of Vit-E (200 mg/kg) induced hepato-
toxicity, which is in agreement with the result of Tremblay
(2014) who indicated that body stores fat-soluble vitamins,
such as vitamins A and D, in liver tissue. When we consume
too much of these vitamins, they accumulate within liver, even-
tually proving toxic to liver cells and reducing liver function.
High doses of vitamin B-3, or niacin, can also damage liver.
Liver toxicity has a number of possible symptoms.
In conclusion, the present results demonstrated that 50 and
100 mg/kg were the most potent doses of the vitamin E in sig-
niﬁcantly decreasing the chromosomal aberrations, increasing
the mitotic index and reducing the hepato-pathological lesions
toward the negative control value. In contrary, the less effec-
tive dose of vitamin E on the preceding parameters was the
higher dose (200 mg/kg). The lowest two doses (50, 100 mg/
kg) showed more or less similar effects but with higher efﬁcacy
than that of the highest dose.
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